IGC — IGC Pharma Balance Sheet
0.000.00%
- $28.57m
- $29.30m
- $1.27m
Annual balance sheet for IGC Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 9 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-KT |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 10.5 | 3.35 | 1.2 | 0.405 | 0.938 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.597 | 0.131 | 0.091 | 0.077 | 0.075 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 15.1 | 6.47 | 3.71 | 2.9 | 1.79 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 9.87 | 8.54 | 3.89 | 3.32 | 2.15 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 26.8 | 17.2 | 9.9 | 8.75 | 9.71 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.44 | 1.9 | 2.34 | 2.26 | 2.16 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.94 | 2.27 | 2.58 | 2.42 | 2.29 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 23.9 | 14.9 | 7.32 | 6.33 | 7.42 |
| Total Liabilities & Shareholders' Equity | 26.8 | 17.2 | 9.9 | 8.75 | 9.71 |
| Total Common Shares Outstanding |